-
-
-
-
-
-
-
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
-
-
-
-
-
-
-
UPDATE: William Blair Starts Neurocrine Bio. (NBIX) at Outperform
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
-
-
-
-
-
-
-
Neurocrine Bio. (NBIX) PT Raised to $103 at Piper Jaffray
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): 3 Reasons INGREZZA Is Better Positioned Than AUSTEDO - Oppenheimer
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): License Deal Favorable Terms - Piper Jaffray
-
-
-
-
-
-
-
Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
-
12,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All